Avasimibe
-
Avasimibe
structure -
-
CAS No:
166518-60-1
-
Formula:
C29H43NO4S
-
Chemical Name:
Avasimibe
-
Synonyms:
Sulfamic acid,N-[2-[2,4,6-tris(1-methylethyl)phenyl]acetyl]-,2,6-bis(1-methylethyl)phenyl ester;Sulfamic acid,[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-,2,6-bis(1-methylethyl)phenyl ester;CI 1011;Avasimibe;PD 148515;Avasimin;2,6-Diisopropylphenyl (2-(2,4,6-triisopropylphenyl)acetyl)sulfamate
- Categories:
-
CAS No:
Description
Avasimibe is an oral inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively.
Avasimibe is a monoterpenoid.|Avasimibe is an orally bioavailable inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) that prevents cholesterol deposition in the arterial wall. Research was discontinued due to difficulties in assaying the effects of avasimibe on preventing plaque formation and due to its ability to increase the activity of Cytochrome P450 3A4, thus increasing the removal of other drugs from the body.
Avasimibe Basic Attributes
501.72102
501.72
1592732-453-0
28LQ20T5RC
DTXSID80168117
C75252
2935009090
Characteristics
80.8
8.2
white to tan
1.072±0.06 g/cm3(Predicted)
178-180° (Lee); mp 169.5-170.4° (Dozeman)
1.529
DMSO: ≥40mg/mL
room temp
Drug Information
Investigated for use/treatment in peripheral vascular disease.
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inducers.)
2,6-bis(1-methylethyl)phenyl ((2,4,6-tris(1-methylethyl)phenyl)acetyl)sulfamate
Avasimibe Use and Manufacturing
Avasimibe is a selective inhibitor of Cholesterol Acyltransferase 1 and CYP2C9. Avasimibe is known to induce apoptosis of glioma cell lines as a model of glioblastoma.
Computed Properties
Molecular Weight:501.7
XLogP3:8.2
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:4
Rotatable Bond Count:10
Exact Mass:501.29128003
Monoisotopic Mass:501.29128003
Topological Polar Surface Area:80.8
Heavy Atom Count:35
Complexity:734
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Latest News on Avasimibe
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4